Shattuck Labs (NASDAQ:STTK) Insider Abhinav Shukla Sells 23,365 Shares

Shattuck Labs, Inc. (NASDAQ:STTK) insider Abhinav Shukla sold 23,365 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the transaction, the insider owned 86,380 shares of the company’s stock, valued at $611,570.40. This represents a 21.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shattuck Labs Price Performance

NASDAQ STTK opened at $7.05 on Friday. Shattuck Labs, Inc. has a 1-year low of $0.71 and a 1-year high of $8.33. The company has a market capitalization of $540.60 million, a P/E ratio of -11.19 and a beta of 1.05. The business has a 50 day moving average price of $5.97 and a 200 day moving average price of $5.26.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same quarter in the previous year, the company earned ($0.27) EPS. On average, research analysts expect that Shattuck Labs, Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings upgraded Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 16th. Cantor Fitzgerald started coverage on shares of Shattuck Labs in a research note on Monday, April 27th. They set an “overweight” rating for the company. Wedbush increased their price objective on shares of Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. TD Cowen reissued a “buy” rating on shares of Shattuck Labs in a research report on Friday, March 6th. Finally, Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 target price for the company in a report on Friday, June 5th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Shattuck Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Hedge Funds Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently made changes to their positions in STTK. Virtu Financial LLC acquired a new stake in Shattuck Labs during the 3rd quarter valued at $38,000. AQR Capital Management LLC boosted its position in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Shattuck Labs in the 2nd quarter valued at about $44,000. Squarepoint Ops LLC acquired a new stake in shares of Shattuck Labs during the third quarter valued at about $46,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of Shattuck Labs by 147.5% during the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.